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Mevalonate diphosphate decarboxylase (MVD) is an ATP-dependent enzyme that catalyzes the phosphorylation/decarboxyl-
ation of (R)-mevalonate-5-diphosphate to isopentenyl pyrophosphate in the mevalonate (MVA) pathway. MVD is a key enzyme
in engineered metabolic pathways for bioproduction of isobutene, since it catalyzes the conversion of 3-hydroxyisovalerate
(3-HIV) to isobutene, an important platform chemical. The putative homologue from Picrophilus torridus has been identified as
a highly efficient variant in a number of patents, but its detailed characterization has not been reported. In this study, we have
successfully purified and characterized the putative MVD from P. torridus.We discovered that it is not a decarboxylase per se
but an ATP-dependent enzyme, mevalonate-3-kinase (M3K), which catalyzes the phosphorylation of MVA tomevalonate-3-
phosphate. The enzyme’s potential in isobutene formation is due to the conversion of 3-HIV to an unstable 3-phosphate inter-
mediate that undergoes consequent spontaneous decarboxylation to form isobutene. Isobutene production rates were
as high as 507 pmol min1 g cells1 using Escherichia coli cells expressing the enzyme and 2,880 pmol min1 mg protein1 with
the purified histidine-tagged enzyme, significantly higher than reported previously. M3K is a key enzyme of the novel MVA path-
way discovered very recently in Thermoplasma acidophilum. We suggest that P. torridusmetabolizes MVA by the same pathway.
The mevalonate (MVA) pathway (1) is the main route for theproduction of isopentenyl pyrophosphate (IPP) from acetyl
coenzyme A (acetyl-CoA) in a diverse cohort of organisms, in-
cluding higher eukaryotes, archaea, a few eubacteria, fungi, and
plants (2). IPP is a key building block for a large family of metab-
olites such as isoprenoids, dolichols, and sterols that are crucial for
a wide variety of cellular functions (3). Many of these molecules
have found applications inmedicine and agriculture or are used as
nutraceuticals, flavors, and fragrances (4, 5). Inhibition of the
MVA pathway may also be a target for the design of antibacterial
drugs (6).
More recently, the emergence of industrial synthetic biology
has led to more and more examples of metabolic engineering us-
ing enzymes from theMVApathway for sustainable production of
bioactive and industrial chemicals (7). Products include amor-
pha-4,11-diene (the precursor to artemisinin) (8, 9), limonene
and -carotene (10–12), a range of sesquiterpenes with potential
applications in cosmetics, pharmaceuticals, and jet fuels (13–15),
and other biofuels, such as prenol, isoprenol, or other C5 com-
pounds (16, 17).
A noteworthy example is the use of mevalonate diphosphate
decarboxylase (EC 4.1.1.33) (MVD) to produce isobutene. In the
classical MVA pathway, MVD catalyzes the final step, where it
produces IPP from (R)-mevalonate-5-diphosphate (MVAPP) in
an irreversible reaction dependent uponATP (Fig. 1A).MVAPP is
phosphorylated first, and consequent decarboxylation occurs
with the concomitant release of inorganic phosphate. With the
same mechanism, classical MVDs also catalyze the conversion of
the nonphosphorylated 3-hydroxyisovalerate (3-HIV) to isobutene
(Fig. 1B) (18). Isobutene is a small, highly reactive molecule, used
extensively as a platform chemical to manufacture a wide variety of
products (19, 20) including fuel additives, rubbers, and speciality
chemicals. The global demand for isobutene produced from petro-
chemical sources was estimated to be around 10 million metric tons
per year with a market value higher than 15 billion euros (21, 22).
Sustainable conversion of renewable feedstocks to isobutene using
engineered pathways containing MVD is, therefore, an important
target, although current microbial processes are still unsatisfactory
(20) compared with current petrochemical production. Neverthe-
less, Global Bioenergies (Evry, France) has recently announced a sec-
ond pilot plant study (23).
The first demonstration of isobutene production viaMVDem-
ployed Escherichia coli engineered with the Saccharomyces cerevi-
siaemevalonate diphosphate decarboxylase homologue (ScMVD)
to catalyze the conversion of 3-HIV (18). A patent regarding the
production of 3-HIV from acetone and acetyl-CoA was filed sub-
sequently (24), followed by further patents on the utilization of
MVDs from different sources to produce isobutene more effi-
ciently (25, 26). The concept was also extended to production of
other molecules such as isoprenol (27, 28).
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Among the enzymes tested in the patents, one of the most
efficient decarboxylases for isobutene production (25, 27) is the
enzyme from Picrophilus torridus (GenBank [29] accession no.
AAT43941; locus tag PTO1356), which has been annotated as an
MVD (29, 30). The utilization of the putative P. torridus MVD
(putPtMVD) alone resulted in greater production titers, but even
higher yields were obtained when putPtMVD was mixed with
MVDs from other organisms (26, 28). To explain this, it has been
proposed that putPtMVD catalyzes phosphorylation of the sub-
strate faster than the subsequent decarboxylation. It has further
been proposed that the phosphorylated intermediate is released
and the additional mixture of other MVDs catalyzes decarboxyl-
ation of this intermediate to isobutene, providing an overall in-
crease in efficiency (26, 28). However, this hypothesis remains to
be tested, since putPtMVD has not yet been purified and charac-
terized, and the reaction mechanism has not been confirmed.
In the interest of unveiling more information on this poorly
characterized enzyme and its potential for isobutene formation,
we investigated putPtMVD inmore detail. After sequence analysis,
putPtMVD was tested on the putative natural substrate MVAPP
andonother potential substrates.We found that the enzyme is not
anMVD. Instead, it belongs to a new class of enzyme,mevalonate-
3-kinase (M3K), very recently discovered in Thermoplasma acido-
philum (31, 32). Finally, putPtMVD’s ability to produce isobutene
from 3-HIV and its potential to produce other valuable small alk-
enes were investigated. Isobutene production rates were signifi-
cantly higher than reported previously (18).
This study provides important insights into a new enzyme in-
volved in the production of isoprenoids. Since M3Ks belong to a
new class of enzymes, there is considerable scope to discover new
biocatalysts with potential industrial uses. In particular, M3K cat-
alyzes isobutene formation at a higher rate than other biocatalysts.
MATERIALS AND METHODS
Materials. Bacterial strains and plasmids were purchased from Novagen.
Enzymes for gene cloning and strain transformationwere purchased from
Fermentas, while purification kits for genes and plasmids were purchased
fromQiagen.Materials for protein purification and SDS-PAGEwere pur-
chased from GE Healthcare and Bio-Rad. 3-Hydroxyisovalerate (3-HIV)
was purchased from TCI Chemicals, and 3-hydroxypropionate was pur-
chased from Manchester Organics. All other chemicals were purchased
from Sigma-Aldrich unless stated otherwise.
Sequence and structure analysis. Sequences were searched with
BLASTp (33) using the putPtMVD amino acid sequence (GenBank [29]
accession no. AAT43941) within nonredundant sequences database (No-
vember 2014). The E value cutoff was set at 0.1, and the 47most significant
hits were aligned with MUSCLE (34). Phylogenetic reconstruction was
performed with MEGA6 (35) by the maximum likelihood test.
For multiple-sequence alignment of classical MVDs and Thermoplas-
matales putativeMVDs, amino acid sequences used were from the follow-
ing organisms (with the respective GenBank [29] accession no. shown in
parentheses): Staphylococcus epidermidis (AAO03959), Saccharomyces
cerevisiae (AAC49252), Legionella pneumophila (AAU28109), Trypano-
soma brucei (EAN78728), Candida albicans (AAF19399), Homo sapiens
(AAC50440),Musmusculus (CAC35731), Rattus norvegicus (AAB00192),
Arabidopsis thaliana (AEE79204), Ginkgo biloba (AAV32433), Staphylo-
coccus aureus (BAB56753), Streptococcus pyogenes (AAK33797), Strepto-
coccus pneumoniae (CCP34068), Thermoplasma volcanium (BAB59465),
Thermoplasma acidophilum (CAC12426), Ferroplasma acidarmanus
(AGO61795), and Picrophilus torridus (AAT43941). Alignment was gen-
erated using MUSCLE (34) and rendered with ESPript (36).
Cloning. Genes encoding putPtMVD and ScMVD, optimized for ex-
pression in E. coli (see Fig. S2 and Fig. S3 in the supplemental material),
were synthesized by Biomatik with the inclusion of NdeI andNotI restric-
tion sites to facilitate insertion into a modified version of plasmid pET-
20b(), adapted for N-terminal histidine tagging. Escherichia coli
BL21(DE3)pLysS was transformed by heat shock, and the transformants
were selected on LB agar plates supplemented with carbenicillin (50 g/
ml), chloramphenicol (34g/ml), and glucose (10 g/liter). E. coliwas also
transformed with the empty plasmid and used as a control. Glycerol
stocks (8%) of transformants were stored at 80°C, and experimental
cultures were derived from single colonies grown overnight on LB agar at
37°C. For expression or whole-cell biotransformation assays, single colo-
nies from those plates were used to inoculate precultures.
Expression and purification.Overnight precultures (50 ml) of E. coli
strains were grown in LBmedium (500ml) with antibiotics and incubated
at 37°C with shaking at 160 rpm. At an optical density at 600 nm (OD660)
of approximately 0.6, protein expression was induced by adding isopro-
pyl--D-1-thiogalactopyranoside (IPTG) (0.4 mM). After 14 h, cells were
removed by centrifugation and resuspended in buffer A (20 mM sodium
phosphate, 30 mM imidazole, 500 mM NaCl [pH 7.4]) for subsequent
purification or in buffer B (50 mM Tris-HCl, 10 mMMgCl2, 20 mM KCl
[pH7.5])when the supernatantswere to be used directly as crude extracts.
The cells were lysed with a Constant Systems cell disruption system, cell
debris was removed by centrifugation at 15,000  g for 15 min, and
protein expression was checked by SDS-PAGE (see below).
putPtMVD and ScMVD were purified at 4°C using an Akta protein
purification system. Crude extracts (10 ml) were applied to a HisTrap FF
crude column (1 ml), and proteins were eluted with a linear gradient of
buffer A containing 500 mM imidazole (1 ml/min). Elution was moni-
tored by UV (280 nm). Fractions (2ml) were analyzed by SDS-PAGE (see
below), and those containing the protein of interest were combined. Buf-
fer Awas exchangedwith buffer B by several concentration/dilution cycles
using a Vivaspin sample concentrator. Fresh enzymes were used each
time.
SDS-PAGE was done with a Mini-Protean electrophoresis system us-
ing TGX precast gels stained with QC colloidal Coomassie protein stain.
Puritywas estimated by visual observation. Total protein concentration in
crude extracts was determinedwith the Bio-RadDCprotein assay kit. The
concentrations of pure putPtMVD and ScMVDwere calculated from A280
measurements with a NanoDrop ND1000 spectrophotometer (Thermo
Scientific) using a computed extinction coefficient of 22,015 and 53,650
M1 · cm1, respectively.
Enzyme assays. The activity of purified putPtMVD and ScMVD was
determined by coupling the release of ADP with NADH oxidation by
pyruvate kinase/lactate dehydrogenase (PK/LDH) (37-41), measured at
340 nmat 10-s intervals using anAgilent 8453UV-visible spectrophotom-
eter. Assays were performed in 1-ml polymethyl methacrylate cuvettes
(BRAND) at 30°C in buffer Bwith the addition of 0.2mMNADH, 0.5mM
phosphoenolpyruvate (PEP), 5 mM ATP, aqueous glycerol solution of
PK/LDH (20 l) (catalog no. P0294; Sigma-Aldrich), and 10 to 50 g of
FIG 1 MVD reaction scheme. (A) The natural substrate of MVD is (R)-me-
valonate-5-diphosphate (MVAPP), which is converted to isopentenyl pyro-
phosphate (IPP). (B) MVD is also active on 3-hydroxyisovalerate (3-HIV) to
produce isobutene in S. cerevisiae (18).
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pure enzyme. Assays were equilibrated for 2 min and initiated by the
addition of substrate (see below). NADH concentrations were calculated
using an extinction coefficient of 6,220 M1 · cm1. One unit of enzyme
activity corresponds to production of 1 mol NADH per 1 min.
Substrate range andkinetic characterization. putPtMVDandScMVD
were tested for activity with (R,S)-mevalonate-5-diphosphate (MVAPP),
(R,S)-mevalonate-5-phosphate (MVA-5P), and (R)-mevalonate (MVA),
all at 500 M. putPtMVD was also tested for activity with 3-hydroxy-
isovalerate (3-HIV), 3-hydroxybutyrate (3-HB), and 3-hydroxypropi-
onate (3-HP), at the same concentration.
For putPtMVDkinetic characterization, theMVA concentration range
was 75 to 900 M, and the 3-HIV and 3-HB concentrations range from 1
to 25 mM. For ScMVD kinetic characterization, the MVAPP concentra-
tion range was 50 to 300 M. When performing kinetic analyses for the
cosubstrate ATP,MVA andMVAPPwere kept in excess (2mM) and ATP
was kept in a range between 18.75 and 300 M. Maximum velocities
(Vmax) andMichaelis constants (Km) were estimated using theMichaelis-
Menten model of GraphPad Prism version 6.04.
Product identification. For isoprenol analysis by gas chromatogra-
phy-mass spectrometry (GC-MS) and phosphorylated MVA identifica-
tion by electrospray ionization-mass spectrometry (ESI-MS), products
were generated in reactionmixtures (1ml) containing 5mMMVA, 6mM
ATP, and 50 g pure putPtMVD in buffer B at 30°C with shaking at 200
rpm. Incubation times are stated in the text. Control samples were pre-
pared in the same way but without adding the enzyme.
Enzymatic reaction mixtures for nuclear magnetic resonance (NMR)
were incubated for 24 h at 30°C with shaking at 200 rpm in reaction
mixtures described previously (31) but using a larger volume (300l) and
a higher concentration ofMVAandPEP (40mM). Analytical standards of
MVA and MVA-5P were prepared at a concentration of 40 mM.
Formation of isobutene and other gaseous alkenes. Isobutene forma-
tionwas investigated forbothputPtMVDandScMVDusingwhole cells, crude
extracts, and pure enzymes. Isobutene formation was linear until 48 h, so
production rates were calculated during this period. putPtMVD was also
tested for ethene and propene formation from 3-HP and 3-HB, respectively,
in crude extracts and with purified enzyme. Quantification of all gases was
performed by GC-MS.
(i) Whole-cell assays. E. coli strains were grown and induced as de-
scribed above. After 5 h, cells were collected by centrifugation at 15,000
g for 15min and resuspended in freshmedium containing IPTG. Reaction
mixtures (10 ml) containing harvested cells (20 g/liter) and 3-HIV (50
mM) were incubated at 37°C with shaking at 200 rpm in 30-ml glass vials
closed with gas-tight caps with polytetrafluorothylene (PTFE)-silicone
septa.
(ii) Crude extract and pure enzyme assays. Reactionmixtures (1 ml)
containing crude extracts (1 mg/ml total protein) or pure putPtMVD and
ScMVD (50 g), ATP (40 mM), and either 3-HIV, 3-HB, or 3-HP (40
mM) in buffer B were incubated at 30°Cwith shaking at 200 rpm in sealed
GC vials (nominal volume of 2 ml) with PTFE screw caps. For controls,
samples without the addition of enzymes were also analyzed. The reaction
mixtures were incubated at the temperatures stated in the text.
Analytical methods. (i) GC-MS. Samples were analyzed using an Agi-
lent 7890A GC-MS system equipped with a Restek Rxi-5ms capillary col-
umn (0.25 mm by 30 m by 0.25 m) and a 5975C inert mass selective
detector (MSD) with a quadrupole mass analyzer. Helium was used as a
carrier gas at 1.2 ml/min. Data analysis was done using the Agilent MSD
ChemStation software and by comparison with the mass spectra and re-
tention times of authentic standards.
For detection and quantification of isoprenol, samples of reaction
mixtures (250l) were extractedwith 750l ethyl acetate, and the solvent
phase (1 l) was injected at an inlet temperature of 250°C and at a split
ratio of 100:1. The oven temperature was kept at 45°C for 5min, increased
to 300°C at 20°C/min, and then held for 5 min. The retention time of
authentic isoprenol was 3.32 min, and a linear calibration curve was ob-
tained over a concentration range from 0.1 to 10 mM.
For detection and quantification of isobutene, propene, and ethene,
the headspace (100 l) was manually injected at an inlet temperature of
150°C and at a split ratio of 100:1. The oven temperature was kept at 40°C
for 5 min, increased to 200°C at 20°C/min, and then held for 5 min. The
retention times of authentic isobutene, propene, and isobutene were 1.42,
1.38, and 1.34 min, respectively. A linear calibration curve was obtained
for all gases over a concentration range from4,000 to 200,000 pmol/ml. At
low product concentrations, sensitivity was increased by monitoring the
most characteristic ions in selected ion monitoring (SIM) mode. For
isobutene, the ions were 39, 41, and 56m/z; for propene, they were 39, 41,
and 42 m/z; for ethene, they were 26 and 27 m/z.
(ii) ESI-MS. Reaction mixtures were filtered using a Vivaspin sample
concentrator to remove enzyme and quench the reaction. Filtrates were
analyzed by ESI-MS operating in the negative ion mode using a Varian
310-MS triple quadrupole (TQ) system controlled by a Varian Worksta-
tion version 6.9. Samples were diluted in 50% water–50% acetonitrile for
direct infusion at 0.05 ml/min. Multiple spectra (10 spectra) were aver-
FIG 2 Phylogenetic analysis. P. torridus putative MVD is indicated by a red
circle. The color of the line before the organism name in the dendrogram
shows the kingdom of the organism as follows: red line, the Bacteria kingdom;
blue line, the Fungi kingdom; green line, the Chromalveolata kingdom; black
line, the Archaea kingdom. The black bracket indicates archaea belonging to
the Thermoplasmatales order.
M3K from P. torridus
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aged to generate the data used in the figures. The masses of the negatively
charged ions discussed are mevalonate-3-phosphate (227 m/z) and me-
valonate (147 m/z), and the phosphate species are H2PO4 (97 m/z) and
PO3 (79 m/z). For tandem MS (MS-MS) acquisition, the isolation width
was set at 1 m/z, and the collision energy was set at 10 eV.
(iii) NMR. The samples were diluted to 600 l with 99.9% D2O.
Spectra were acquired at ambient temperature using a 500-MHz
Bruker AV(III)500 spectrometer equipped with a cryoprobe. Data
were processed and analyzed using ACD/NMR Processor version
12.01.
FIG 3 Multiple-sequence alignment. ConventionalMVDs are indicated in black, and “MVD-like” proteins from theThermoplasmatales order are shown in red.
Only highly conserved regions (outlined in blue) are depicted. Conservation of residues is denoted by colors: white amino acids on a red background are strictly
conserved; red amino acids on a white background are high in similarity. The numbering annotation is based on S. epidermidis MVD. Stars denote residues
involved in MVAPP interaction (cyan for C-1 carboxylate group and blue for diphosphate moiety and hydroxyl group). Triangles denote residues involved in
ATP interaction (red for phosphate groups, orange for purine ring and ribose).
TABLE 1 Kinetic constants of ScMVD, putPtMVD, PMD from H. volcanii and R. castenholzii, and M3K from T. acidophiluma
Enzyme Reference(s) Activity (U · mg1) Km (M)
b Km(ATP) (M) kcat (s
1) kcat/Km (s
1 · M1)b
P. torridus putMVD 3 0.1 131 18 (MVA) 23 0.1 1.9 1.5 102 (MVA)
S. cerevisiae MVD This study 7 0.7 133 28 (MVAPP) 61 6 5.4 4 102 (MVAPP)
S. cerevisiae MVD 39, 40 6.4 0.2 123 22 (MVAPP) 61 6 4.9 4 102 (MVAPP)
H. volcanii PMD 44 5.6 0.1 159 15 (MVA-5P) 289 15 3.5 2.2 102 (MVA-5P)
R. castenholzii PMD 45 NA 152 38 (MVA-5P) NA 1.7 1.1 102 (MVA-5P)
T. acidophilum M3K 31 NA 97 6 (MVA) NA 5.0 5.1 102 (MVA)
a Activity values refer to the rate of ADP formation coupled to NADH oxidation. Values for putPtMVD and ScMVD are calculated from enzyme assays at 30°C in 50 mM Tris-HCl
buffer, pH 7.5, with the addition of 10 mM MgCl2, 20 mM KCl, and 10 g of pure
putPtMVD or ScMVD. Assays were done in triplicate, and the means standard errors of the
means for the kinetic constants are shown. Previous data for ScMVD, H. volcanii PMD, R. castenholzii PMD, and T. acidophilum M3K are taken from the literature. NA, not
available.
b Values are given for the respective substrate (in parentheses) of each enzyme (MVAPP, MVA-5P, or MVA).
Rossoni et al.
2628 aem.asm.org April 2015 Volume 81 Number 7Applied and Environmental Microbiology
 o
n
 M
arch 12, 2015 by Univ of Nottingham
http://aem
.asm
.org/
D
ow
nloaded from
 
RESULTS
Sequence analysis. Initially, a bioinformatics approach was used
to gain insights into the possible functionality of putPtMVD. A
BLASTp search for putPtMVD homologues and a phylogenetic
analysis revealed that proteins with the highest sequence identity
and similarity with putPtMVDare foundmostly inmembers of the
Archaea domain, with higher values with enzymes from Ferro-
plasma acidarmanus, Thermoplasma volcanium, and T. acidophi-
lum, allmembers of theThermoplasmatales order (Fig. 2; see Table
S1 in the supplemental material). Interestingly, putPtMVD has se-
quence identity and similarity of only 21% and 41%, respectively,
with Staphylococcus epidermidis MVD (SeMVD) (38), and only
18% and 36% with ScMVD (42), two enzymes that have been
verified to act catalytically as MVDs. This significant difference
opens the possibility that putPtMVD, and the other Thermoplas-
matales homologues, may be unrelated to classical MVDs.
To further investigate this hypothesis, a multiple-sequence
alignment was made between Thermoplasmatales homologues
and classical MVDs to compare important conserved regions and
residues known to be involved in substrate binding and enzyme
activity (Fig. 3). The classical MVDs were chosen on the basis of
their experimentally verified ability to catalyze decarboxylation of
MVAPP and the availability of structural, functional, and muta-
tion data. The regions for ATP binding and interaction with the
FIG 4 ESI-MS analysis. All spectra were collected in negative ion mode. The mass spectra are shown. (A) Control sample containing MVA but without added
enzyme; (B) sample containingMVA and putPtMVD; (C)MS-MS spectrum of 227m/z ion yielding phosphate ions (97 and 79m/z). The reaction was performed
in 50 mM Tris-HCl buffer, pH 7.5, with the addition of 10 mM MgCl2 and 20 mM KCl. Samples were analyzed after 24 h.
M3K from P. torridus
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C-1 carboxylate of MVAPP are very similar among the whole co-
hort (Fig. 3, positions 12, 101 to 111, and 144). However, strong
differences are seen in those regions particularly suggested to be
involved in the binding of the diphosphate moiety of MVAPP or
directly involved in the catalytic mechanism (Fig. 3, positions 17
to 21, 72, 139 to 141, 192 to 196, and 283). This information
suggests that putPtMVD may differ significantly from classical
MVDs (18 to 21% sequence identity). In fact, it shares greater
sequence identity (38%)with the newly discoveredT. acidophilum
mevalonate-3-kinase (TaM3K) (31, 32) (Fig. 3), which was also
previously annotated as anMVD. UnlikeMVDs, the substrate for
TaM3K is (R)-mevalonate (MVA), and the enzyme acts as a kinase
to produce (R)-mevalonate-3-phosphate (MVA-3P) and not as a
decarboxylase (31, 32). The crystal structure of TaM3K was very
recently described, and the importance of some of the amino acid
differences mentioned above in comparison to classical MVDs
was confirmed (43).
Nevertheless, the sequence identity between TaM3K and
putPtMVD is still relatively low, leaving questions about their
functional similarity. Since putPtMVD is an important indus-
trial enzyme, we decided to investigate the substrate specificity
and reaction selectivity to identify its real biological function.
Search for putPtMVD’s natural substrate.The sequence of the
gene encoding putPtMVD was optimized for expression in E. coli
(see Fig. S2 in the supplemental material), transformed, and ex-
pressed in E. coli BL21(DE3)/pLysS with an N-terminal histidine
tag (6His). Overnight expression under IPTG induction lead to
synthesis of a protein of around 40 kDa that, after purification on
a Ni Sepharose column, was at least 95% pure.
Activity was investigated using a coupled enzymatic assay al-
ready in use for the analysis of substrate phosphorylation by clas-
sical MVDs (37–41). There was no activity when MVAPP was
tested as the substrate. (R,S)-Mevalonate-5-phosphate (MVA-5P)
was also tested, since this is the substrate for another enzyme,
MVA-5P decarboxylases (phosphomevalonate decarboxylase
[PMD]), similar toMVD, and recently discovered in Archaea and
Bacteria (44, 45). However, there was no detectable activity on
MVA-5P. Finally, MVA was tested as well, since it is the substrate
for TaM3K (31, 32). With MVA, activity was detected at a rate of
3.01 U mg1 (Table 1). Overall, the substrate range is consistent
with the hypothesis that putPtMVD is actually an M3K, similar to
TaM3K, rather than a classical MVD, since it did not act on
MVAPP. As a comparison, the classical ScMVD (sequence avail-
able in Fig. S3 in the supplemental material) was expressed and
purified in the same way as putPtMVD and tested on the same
substrates. As expected, ScMVD activity was observed only with
MVAPP and not with MVA-5P or MVA (Table 1).
In order to understandwhetherMVA is putPtMVD’s natural sub-
strate, we measured and compared the kinetic parameters for MVA
phosphorylation by putPtMVDwithMVAPPphosphorylation by Sc-
MVD(Table 1). Thekinetic parameters forScMVDwere very similar
to those reported previously (Table 1) (39, 40). Themagnitude of the
kinetic constants and activities of putPtMVDwithMVAwere similar
to those of ScMVDwithMVAPP, consistentwith the hypothesis that
MVA is the natural substrate of putPtMVD, asMVAPP is for ScMVD.
In addition, the kinetic parameters reported in the literature for the
newly discovered PMDs from Haloferax volcanii (44) and Rosei-
flexus castenholzii (45), and of M3K from T. acidophilum are also
similar in magnitude (Table 1).
New enzyme classification of putPtMVD. To discriminate be-
tween putPtMVD being an MVD or an M3K, further experiments
were needed, since the coupled enzyme assay monitors only ADP
release and not the actual decarboxylation of the intermediate.
The expected reaction product would be 3-methylbut-3-en-1-ol
(isoprenol) if MVA is phosphorylated and then decarboxylated.
Therefore, attempts were made to detect isoprenol by gas chro-
matography-mass spectrometry (GC-MS). Pure putPtMVD was
mixed with a high concentration of MVA (5 mM), and the pres-
ence of isoprenol was checked at intervals (24, 48, and 96 h). Even
after a long incubation time (96 h), isoprenol was not observed,
FIG 5 NMR analysis. The full spectrum is available in the supplemental ma-
terial (see Fig. S6 in the supplemental material). The MVA-3P structure is
shown at the top, and the peaks corresponding to carbons 1 to 6 are shown at
the bottom.Values are in parts permillion (ppm). The reactionwas performed
as previously described (31) using MVA as the substrate at a concentration of
40 mM. Samples were analyzed after 24 h.
FIG 6 M3K reaction scheme. (A) The natural substrate of M3K is (R)-meval-
onate (MVA), which is converted to (R)-mevalonate-3-phosphate (MVA-3P).
(B) PtM3K is also active on 3-hydroxyisovalerate (3-HIV) and 3-hydroxybu-
tyrate (3-HB) to produce 3-phosphoisovalerate (3-PIV) and 3-phosphobu-
tyrate (3-PB), respectively.
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suggesting that putPtMVD does not catalyze MVA decarboxyl-
ation per se.
Therefore, we tested putPtMVD for formation of a phosphory-
lated product fromMVA, analyzing the reaction product by elec-
trospray ionization-mass spectrometry (ESI-MS). An ion with
m/z 227 was detected only in the samples where putPtMVD was
added to the reactionmixture, which corresponded to themass of
the expected phosphorylated MVA (Fig. 4B). In the control with-
out added enzyme, this ion was not present. Instead, an ion with
147 m/z was among those with the highest intensity, correspond-
ing to unreacted MVA (Fig. 4A). A higher background noise was
observed in theMS trace for the control compared to the test. This
was probably due to a lower response of MVA in the ESI-MS
analysis compared to the phosphorylated MVA. Unreacted MVA
was also observed in samples where the enzyme was added, mean-
ing that full conversion was not reached (Fig. 4B). As a confirma-
tion that the 227 m/z ion corresponded to phosphorylated MVA,
MS-MS analysis of the isolated product generated peaks corre-
sponding to phosphate ions (H2PO4
 [97m/z] andPO3
 [79m/z]
[Fig. 4C]).
Although the phosphorylated MVA product is likely to be
MVA-3P, it must be mentioned that the observed 227 m/z ion
could also correspond to MVA-5P, the alternative phosphoryla-
tion product. Therefore, we used 13C NMR analysis to distinguish
between the two isomers by analyzing the coupling between 13C
and 31P. Any coupling will result in fine structure (doublets) asso-
ciated with the signals for each carbon atomwithin three bonds of
31P. The 13C NMR spectrum of authentic MVA showed six singlet
peaks, whereas the spectrum of authentic MVA-5P showed split-
ting at carbons 4 and 5 as expected (see Fig. S4 and Fig. S5 in the
supplemental material). In contrast, 13C NMR spectrum of the
product mixture after phosphorylation of MVA by pure putPtMVD
showed splitting at carbons 2 to 4 and 6, consistent with phosphory-
lation at position 3 (Fig. 5; see Fig. S6 in the supplemental material).
Thus, analysis of the sequence, substrate range, and reaction
products demonstrated that putPtMVDhas been annotated incor-
rectly and that it is actually a mevalonate-3-kinase that acts on
MVA to produce MVA-3P (Fig. 6A). Therefore, we propose that
“putPtMVD” should be renamed PtM3K. From now on, it is re-
ferred to as PtM3K throughout the text.
Formation of isobutene. PtM3K was identified as a preferred
enzyme for the production of isobutene from 3-HIV (25). There-
fore, activity ofPtM3Kon 3-HIVwas first investigated. Compared
to the natural substrateMVA, the catalytic efficiency was very low,
with a 20-fold-higherKm and a 1,000-fold-lower kcat/Km (Table 2).
The Km and kcat/Km were lower (2.35 mM) and higher (4.25 
105 s1 M1), respectively, than those disclosed previously
(9.17 mM and 2 105 s1 M1 [26]).
Next, isobutene formation was compared using whole cells
expressing PtM3K, crude extract containing PtM3K, and pure
PtM3K (Table 3). Production rates were compared with ScMVD
under the same conditions, since ScMVD also catalyzes isobutene
formation from 3-HIV (18). The experiments were performed in
sealed vials so that isobutene could be measured by GC-MS anal-
ysis of the headspace. Since isobutene can form spontaneously
from3-HIV (46), controlswith no enzymewere always compared,
and the rate of isobutene formation in controls was subtracted
from the enzymatic reactions. As expected (18, 25, 27), both
PtM3Kand ScMVDcatalyzed formation of isobutene (Table 3). In
controls without ATP, isobutene formation was similar to those
observed for controls without enzyme (data not shown). This
confirms that the reactions catalyzed by PtM3K and ScMVD are
ATP dependent. PtM3K catalyzed isobutene formation at rates
consistently higher than ScMVD under all assay conditions. With
the pure enzyme, an 11-fold improvement was observed (Table
3). Very interestingly, a further 110-fold enhancement (from26 to
2,880 pmol min1 mg protein1) was observed for purified
PtM3K when the temperature of the assay was increased from 30
to 50°C (Table 3). However, it must be noted that PtM3K is not a
true decarboxylase but a kinase, and therefore, isobutene production
depends on formation of an unstable intermediate, 3-phospho-
isovalerate (3-PIV) (Fig. 6B) that decarboxylates nonenzymatically.
For this reason, it is possible that the higher production rate observed
at higher temperature is due to an increased rate of spontaneous de-
carboxylation of 3-PIV. We wish to note that the rates of isobutene
formation obtained using PtM3K were even higher than reported
previously using enhanced variants of ScMVDobtainedwith protein
engineering tools (18).
Formation of other gaseous alkenes. In order to test the use of
PtM3K for production of other small, industrially useful alkenes,
TABLE 2 Kinetic constants of PtM3K on four different substratesa
Substrate Activity (U · mg1) Km (M) kcat (s
1) kcat/Km (s
1 · M1)
Mevalonate (MVA) 3 0.1 131 18 1.9 1.5 102
3-Hydroxyisovalerate (3-HIV) 0.17 0.01 2,348 574 0.1 4.25 105
3-Hydroxybutyrate (3-HB) 0.14 0.01 3,163 637 0.1 2.9 105
3-Hydroxypropionate (3-HP) ND ND ND ND
a Activity values refer to the rate of ADP formation coupled to NADH oxidation. Values are calculated at 30°C in 50 mM Tris-HCl buffer, pH 7.5, with the addition of 10 mM
MgCl2, 20 mM KCl, and 50 g of pure PtM3K (for MVA, the amount of pure PtM3K added was 10 g). Assays were done in triplicate, and the means standard errors of the
means for the kinetic constants are shown. ND, not detected.
TABLE 3 Isobutene formation rates for PtM3K and ScMVDa
Enzyme
Isobutene formation rate
Whole cells
(pmol ·
min1 · g
cells1)
Crude extract
(pmol ·
min1 · mg
total
protein1)
Purified protein (pmol ·
min1 · mg protein1)
30°C 50°C
PtM3K 507 137 261 19 26 2 2,880 140
ScMVD 7.4 1.5 1.6 0.3 2.3 1.2 NA
a The concentration of 3-HIV used was 50 mM. For the crude extract and purified
enzyme experiments, 40 mM ATP was added. Assays were done in triplicate, and the
means standard errors of the means for formation rates are shown. Isobutene was
quantified by GC-MS analysis of the headspace. Due to the very low aqueous solubility
of isobutene (51), its concentration in the liquid phase was considered negligible, and it
was not taken into consideration. NA, not available.
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we investigated its activity on two other substrates, 3-hydroxypro-
pionate (3-HP) and 3-hydroxybutyrate (3-HB). These substrates
have the potential to be converted to ethene and propene (19) if
they can be phosphorylated at position 3 and if the intermediates
are sufficiently unstable to decarboxylate spontaneously.
Although the enzymewas able to phosphorylate 3-HB (Fig. 6B)
with kinetics similar to those for 3-HIV (Table 2), no propene was
detected by GC-MS using either crude extract or purified enzyme,
even at a temperature of 50°C. This suggests that, as for MVA, the
phosphorylated intermediate is too stable to decarboxylate. As for
3-HP, the enzyme was not even able to catalyze its phosphoryla-
tion. This suggests that one or two methyl substituents are re-
quired at position C-3 to enable binding of the substrate to the
enzyme and/or for catalytic activity.
DISCUSSION
We demonstrated that the P. torridus enzyme (GenBank [29] ac-
cession no. AAT43941; locus tag PTO1356), so far classified as
mevalonate diphosphate decarboxylase, is actually a mevalonate-
3-kinase, since it acted on MVA to produce MVA-3P (Fig. 6A).
This intermediate appeared to be stable, since no decarboxylation
of MVA was observed and MVA-3P could be detected in the re-
action mixture. Classical MVDs also act as kinases, but MVAPP is
the substrate instead. The phosphorylation results in formation of
a transient tertiary phosphorylated intermediate that quickly re-
leases inorganic phosphate with concomitant decarboxylation
(38, 47, 48) or even in a concerted manner (49). Thus, the differ-
ence in substrate specificity (MVA versus MVAPP) may account
for the differences in the ability of PtM3K and MVDs to act as
decarboxylases. Differences in amino acid composition in regions
suggested to be involved in the catalytic mechanism (Fig. 3, posi-
tions 281 to 284) may also affect the enzymatic mechanism, as
recently confirmed for TaM3K (43).
The results of our sequence analysis suggest that M3Ks may
also be found in othermembers of theThermoplasmatales order in
addition to T. acidophilum (31, 32) and P. torridus. This raises
questions about the pathway forMVAmetabolism in these organ-
isms, since there is little evidence for the operation of the classical
MVA pathway. In the classical MVA pathway, MVA is doubly
phosphorylated toMVAPP and consequently converted to IPP by
MVD (Fig. 7). In the absence of MVD, MVA must undergo a
different route to be converted to IPP. Indeed, the discovery of
TaM3K led to the description of a completely new type of MVA
pathway in T. acidophilum, whereM3K catalyzes the initial step in
the metabolism of MVA (31, 32) (Fig. 7) and MVA-3P-5-kinase
(M3P5K) (GenBank [29] accession no. CAC11895) catalyzes the
conversion of MVA-3P to mevalonate-3,5-bisphosphate (MVA-
3,5PP). The enzymes catalyzing conversion of MVA-3,5PP to iso-
pentenyl phosphate (IP) have not yet been identified, and this
provides an excellent target for future research. IP is finally con-
verted to IPP via IP kinase (IPK) (50).
We have now shown that anM3K is also present in P. torridus.
Since a strongly similar counterpart of M3P5K is also found in
P. torridus (see Table S7 in the supplemental material), P. torridus
is also likely to contain this new type of MVA pathway (Fig. 7). It
should be noted that this pathway is distinct from themevalonate-
5-kinase (M5K) pathway found in Haloferax volcanii (44) and
Roseiflexus castenholzii (45) (Fig. 7). Neither of the key enzymes,
(M5K and PMD) are present in T. acidophilum (50), and there is
no experimental or sequence homology evidence to support their
presence in P. torridus. Overall, this suggests that P. torridus pro-
duces IPP via the newly discovered M3K pathway.
FIG 7 Classical MVA pathway and modified routes. The classical MVA pathway and the modified routes (via M5K and PMD and the newly suggested route in
T. acidophilum) are specifically indicated. Enzyme abbreviations are as follows: M5K, mevalonate-5-kinase; PMK, phosphomevalonate (mevalonate-5-phos-
phate) kinase; MVD, mevalonate-5-diphosphate decarboxylase; PMD, phosphomevalonate (mevalonate-5-phosphate) decarboxylase; IPK, isopentenyl phos-
phate kinase; M3K, mevalonate-3-kinase.
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Regarding the use of PtM3K andMVDs for isobutene produc-
tion, we found that PtM3K exhibits much higher catalytic effi-
ciency than ScMVD. Unlike ScMVD, the potential of PtM3K in
forming the gas is not due to direct decarboxylation but to the
generation of the unstable intermediate, 3-PIV (Fig. 6B). The
isobutene production rates for PtM3K were not disclosed until
now and were found here to be significantly higher than reported
previously for ScMVD (18). Having an enzyme with a higher rate
of isobutene formation from 3-HIV is an important step for the
production of renewable isobutene, since this further reduces the
gap toward commercial application. With ScMVD, it was esti-
mated that the level of cellular activity obtained after enhance-
ment of the enzyme with protein engineering (98 pmol min1 g
cells1 with whole cells [18]) was about 106-fold below what is
needed for a commercial process (18, 20).With PtM3K, the rate is
increased 5-fold (507 pmol min1 g cells1). Although this is still
far from industrial application, the discovery of a new M3K class
of enzymes opens the possibility to screen other, related enzymes
for isobutene formation or to undertake protein engineering to
improve the production rates still further.
As for the potential of PtM3K to be used for the production of
other gaseous alkenes such as ethene and propene, unfortunately,
we were not able to observe any product formation. The enzyme
was able to phosphorylate 3-HB (Fig. 6B and Table 2), but under
the tested conditions, the 3-P intermediate did not spontaneously
decarboxylate to propene. This could be due to the 3-phosphobu-
tyrate (3-PB) intermediate being more stable than 3-PIV. The
absence of an electron-donating methyl group on 3-PB could re-
duce the electron density relative to the tertiary carbon of the
intermediate and slow down the rate of the decarboxylation,
thought to occur via a carbocation intermediate (42).
To conclude, from a microbiological/evolutionary point of
view, our study raises important questions on the presence of
alternativeMVApathways inArchaea. It is even possible that vari-
ant MVA pathways are present among members of all kingdoms
in nature (45). Many plant, bacterial, and fungal enzymes are be-
lieved to participate in the classical MVA pathway, but like
PtM3K, they are still only computationally annotated and need to
be investigated experimentally. Discovery of new enzymes is an
important goal, since this may yield biocatalysts with improved
properties. This can lead to better process efficiencies where pro-
duction yieldswith current enzymes are not yet sufficient for com-
mercial viability and where enzyme stability can be a problem.
Therefore, discovery of new enzymes of the MVA pathways could
aid in improved metabolic engineering for efficient, sustainable
bioproduction of chemicals and fuels.
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